A Phase IIIB Multicenter, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Abatacept Administered Subcutaneously and Intravenously in Subjects With Rheumatoid Arthritis, Receiving Background Methotrexate, and Experiencing an Inadequate Response to Methotrexate.
Latest Information Update: 17 Dec 2021
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Influenza virus vaccine; Pneumococcal vaccine
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics; Registrational; Therapeutic Use
- Acronyms ACQUIRE; MTX-IR Study
- Sponsors Bristol-Myers Squibb
- 15 Apr 2018 Final 5 year safety, efficacy and tolerability immunogenicity results of subcutaneous Abatacept in open label extension period published in The Journal of Rheumatology
- 07 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Oct 2013 Vaccine substudy results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.